Daniela-Elena Oprea-Lager

List of Publications by Year
in descending order

74 papers	3,831 citations	304368 22 h-index	138251 58 g-index
77 all docs	77 docs citations	77 times ranked	3694 citing authors

#	Article	IF	Citations
1	Patient- and Tumour-related Prognostic Factors for Urinary Incontinence After Radical Prostatectomy for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis. European Urology Focus, 2022, 8, 674-689.	1.6	21
2	Evaluation of Oncological Outcomes and Data Quality in Studies Assessing Nerve-sparing Versus Nonâ€“Nerve-sparing Radical Prostatectomy in Nonmetastatic Prostate Cancer: A Systematic Review. European Urology Focus, 2022, 8, 690-700.	1.6	10
3	Predicting early outcomes in patients with intermediateâ€•and highâ€•risk prostate cancer using prostateâ€•specific membrane antigen positron emission tomography and magnetic resonance imaging. BJU International, 2022, 129, 54-62.	1.3	10
4	Prospective analysis of clinically significant prostate cancer detection with [18F]DCFPyL PET/MRI compared to multiparametric MRI: a comparison with the histopathology in the radical prostatectomy specimen, the ProStaPET study. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1731-1742.	3.3	13
5	The clinical characteristics of patients with primary nonâ€•prostateâ€•specific membrane antigenâ€•expressing prostate cancer on preoperative positron emission tomography/computed tomography. BJU International, 2022, 129, 314-317.	1.3	6
6	Modern Imaging in Prostate Cancer: Do We Treat Patients, or Their Scans?. European Urology, 2022, 81, 319-322.	0.9	4
7	Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer. Cancers, 2022, 14, 1169.	1.7	15
8	Standardised uptake values as determined on prostateâ€•specific membrane antigen positron emission tomography/computed tomography is associated with oncological outcomes in patients with prostate cancer. BJU International, 2022, 129, 768-776.	1.3	7
9	Biochemical Persistence of Prostate-specific Antigen after Robot-assisted Laparoscopic Radical Prostatectomy: Tumor localizations using PSMA PET/CT imaging. Journal of Nuclear Medicine, 2021, 62, jnumed.120.252528.	2.8	11
10	Detection of prostate cancer with 18F-DCFPyL PET/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial. World Journal of Urology, 2021, 39, 2439-2446.	1.2	26
11	Detection of Recurrent Prostate Cancer Using Prostate-specific Membrane Antigen Positron Emission Tomography in Patients not Meeting the Phoenix Criteria for Biochemical Recurrence After Curative Radiotherapy. European Urology Oncology, 2021, 4, 821-825.	2.6	42
12	Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 469-476.	3.3	119
13	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancerâ€”2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. European Urology, 2021, 79, 243-262.	0.9	1,545
14	Machine learning-based analysis of [18F]DCFPyL PET radiomics for risk stratification in primary prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 340-349.	3.3	84
15	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part IIâ€”2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. European Urology, 2021, 79, 263-282.	0.9	633
16	The Role of ⁸⁹Zr-Immuno-PET in Navigating and Derisking the Development of Biopharmaceuticals. Journal of Nuclear Medicine, 2021, 62, 438-445.	2.8	39
17	Nuclear Imaging for Bone Metastases in Prostate Cancer: The Emergence of Modern Techniques Using Novel Radiotracers. Diagnostics, 2021, 11, 117.	1.3	6
18	SUVs Are Adequate Measures of Lesional ¹⁸F-DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden. Journal of Nuclear Medicine, 2021, 62, 1264-1269.	2.8	2

#	Article	IF	Citations
19	E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1626-1638.	3.3	188
20	M1a prostate cancer: Results of a Dutch multidisciplinary consensus meeting. BJUI Compass, 2021, 2, 159-168.	0.7	8
21	Management impact of 18F-DCFPyL PET/CT in hormone-sensitive prostate cancer patients with biochemical recurrence after definitive treatment: a multicenter retrospective study. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2960-2969.	3.3	8
22	Interobserver Agreement on Automated Metabolic Tumor Volume Measurements of Deauville Score 4 and 5 Lesions at Interim ¹⁸F-FDG PET in Diffuse Large B-Cell Lymphoma. Journal of Nuclear Medicine, 2021, 62, 1531-1536.	2.8	8
23	Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography in the Evaluation of Initial Response in Candidates Who Underwent Salvage Radiation Therapy after Radical Prostatectomy for Prostate Cancer. Journal of Urology, 2021, 205, 1100-1109.	0.2	4
24	Reply by Authors. Journal of Urology, 2021, 205, 1108-1109.	0.2	0
25	A Systematic Review of the Impact of Surgeon and Hospital Caseload Volume on Oncological and Nononcological Outcomes After Radical Prostatectomy for Nonmetastatic Prostate Cancer. European Urology, 2021, 80, 531-545.	0.9	21
26	Health technology assessment for PSMA-PET: striving towards a cost-effective management of prostate cancer. Clinical and Translational Imaging, 2021, 9, 409-412.	1.1	7
27	Reply by Authors. Journal of Urology, 2021, 205, 1662-1662.	0.2	0
28	The Predictive Value of Preoperative Negative Prostate Specific Membrane Antigen Positron Emission Tomography Imaging for Lymph Node Metastatic Prostate Cancer. Journal of Urology, 2021, 205, 1655-1662.	0.2	10
29	External Validation of Two Nomograms Developed for 68Ga-PSMA-11 Applied to the Prostate-specific Membrane Antigen Tracer 18F-DCFPyl: Is Prediction of the Optimal Timing of Salvage Therapy Feasible?. European Urology Open Science, 2021, 28, 47-51.	0.2	2
30	A Systematic Review of Focal Ablative Therapy for Clinically Localised Prostate Cancer in Comparison with Standard Management Options: Limitations of the Available Evidence and Recommendations for Clinical Practice and Further Research. European Urology Oncology, 2021, 4, 405-423.	2.6	26
31	Irreversible Electroporation and Nivolumab Combined with Intratumoral Administration of a Toll-Like Receptor Ligand, as a Means of In Vivo Vaccination for Metastatic Pancreatic Ductal Adenocarcinoma (PANFIRE-III). A Phase-I Study Protocol. Cancers, 2021, 13, 3902.	1.7	18
32	Biodistribution of ¹⁸F-FES in patients with metastatic ER+ breast cancer undergoing treatment with Rintodestrant (G1T48), a novel selective estrogen receptor degrader. Journal of Nuclear Medicine, 2021, , jnumed.121.262500.	2.8	2
33	External Validation and Addition of Prostate-specific Membrane Antigen Positron Emission Tomography to the Most Frequently Used Nomograms for the Prediction of Pelvic Lymph-node Metastases: an International Multicenter Study. European Urology, 2021, 80, 234-242.	0.9	35
34	Diagnostic Performance of [18F]FDG PET in Staging Grade 1â€“2, Estrogen Receptor Positive Breast Cancer. Diagnostics, 2021, 11, 1954.	1.3	10
35	Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial. Trials, 2021, 22, 768.	0.7	13
36	Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography. Frontiers in Oncology, 2021, 11, 772530.	1.3	14

#	Article	IF	Citations
37	Molecular Targeted Positron Emission Tomography Imaging and Radionuclide Therapy of Pancreatic Ductal Adenocarcinoma. Cancers, 2021, 13, 6164.	1.7	8
38	Oligometastatic Prostate Cancer: Results of a Dutch Multidisciplinary Consensus Meeting. European Urology Oncology, 2020, 3, 231-238.	2.6	30
39	Lesion Detection and Interobserver Agreement with Advanced Image Reconstruction for ¹⁸F-DCFPyL PET/CT in Patients with Biochemically Recurrent Prostate Cancer. Journal of Nuclear Medicine, 2020, 61, 210-216.	2.8	10
40	Repeatability of Quantitative ¹⁸F-DCFPyL PET/CT Measurements in Metastatic Prostate Cancer. Journal of Nuclear Medicine, 2020, 61, 1320-1325.	2.8	22
41	Re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. Eur Urol 2020;78:304â€“6. European Urology, 2020, 78, 310-313.	0.9	9
42	Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial. BMC Cancer, 2020, 20, 884.	1.1	32
43	Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0â€“1 non-small cell lung cancer: the INCREASE trial. BMC Cancer, 2020, 20, 764.	1.1	18
44	Impact of the COVID-19 crisis on imaging in oncological trials. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2054-2058.	3.3	11
45	Quantification of PD-L1 Expression with ¹⁸F-BMS-986192 PET/CT in Patients with Advanced-Stage Nonâ€“Small Cell Lung Cancer. Journal of Nuclear Medicine, 2020, 61, 1455-1460.	2.8	54
46	Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer. PLoS ONE, 2020, 15, e0239414.	1.1	6
47	MP13-13â€ƒVALIDITY OF 18F-PROSTATE-SPECIFIC MEMBRANE ANTIGEN PET/CT DETECTED LESIONS IN PATIENTS WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER IN CLINICAL PRACTICE. Journal of Urology, 2020, 203, e189.	0.2	0
48	MP53-14â€ƒPATIENTS WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY AND A LOCAL RECURRENCE OR NEGATIVE PSMA PET/CT ARE EXCELLENT CANDIDATES FOR SALVAGE RADIOTHERAPY TO THE PROSTATIC FOSSA. Journal of Urology, 2020, 203, .	0.2	0
49	Reply: Quantification of ¹⁸F-DCFPyL Uptake: TBR Versus Patlakâ€™s Analysis. Journal of Nuclear Medicine, 2019, 60, 1834.2-1835.	2.8	1
50	Sensitivity of 18F-fluorodihydrotestosterone PET-CT to count statistics and reconstruction protocol in metastatic castration-resistant prostate cancer. EJNMMI Research, 2019, 9, 70.	1.1	10
51	Simplified Methods for Quantification of ¹⁸F-DCFPyL Uptake in Patients with Prostate Cancer. Journal of Nuclear Medicine, 2019, 60, 1730-1735.	2.8	32
52	Adding multiparametric MRI to the MSKCC and Partin nomograms for primary prostate cancer: Improving local tumor staging?. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 181.e1-181.e6.	0.8	18
53	Healthy Tissue Uptake of 68Ga-Prostate-Specific Membrane Antigen, 18F-DCFPyL, 18F-Fluoromethylcholine, and 18F-Dihydrotestosterone. Journal of Nuclear Medicine, 2019, 60, 1111-1117.	2.8	23
54	Quantitative implications of the updated EARL 2019 PETâ€“CT performance standards. EJNMMI Physics, 2019, 6, 28.	1.3	37

#	Article	IF	Citations
55	First-in-human imaging of nanoparticle entrapped docetaxel (CPC634) in patients with advanced solid tumors using ⁸⁹Zr-Df-CPC634 PET/CT.. Journal of Clinical Oncology, 2019, 37, 3093-3093.	0.8	3
56	Abstract 1415: Staging with [18F]FDG PET/CT. , 2019, , .		0
57	Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of Cancer imaging group. European Journal of Cancer, 2018, 91, 153-163.	1.3	107
58	Prognostic Value of [18 F]-Fluoromethylcholine Positron Emission Tomography/Computed Tomography Before Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 101, 406-410.	0.4	11
59	Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group. Lancet Oncology, The, 2018, 19, e534-e545.	5.1	98
60	Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT. Clinical Genitourinary Cancer, 2017, 15, e773-e782.	0.9	33
61	A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1319-1327.	3.3	15
62	PET-Guided Stereotactic Irradiation of Prostate Cancer Lymph Node Metastases. Journal of Nuclear Medicine, 2017, 58, 183-184.	2.8	1
63	Accuracy and Precision of Partial-Volume Correction in Oncological PET/CT Studies. Journal of Nuclear Medicine, 2016, 57, 1642-1649.	2.8	28
64	Repeatability of Quantitative ¹⁸F-Fluoromethylcholine PET/CT Studies in Prostate Cancer. Journal of Nuclear Medicine, 2016, 57, 721-727.	2.8	22
65	Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review. European Urology, 2016, 70, 416-426.	0.9	51
66	A randomized, phase II study of repeated rhenium-188-HEDP (rhenium) combined with docetaxel versus docetaxel alone in castration resistant prostate cancer (CRPC) metastatic to bone: The Taxium II trial.. Journal of Clinical Oncology, 2016, 34, 5081-5081.	0.8	1
67	Quantification of ¹⁸F-Fluorocholine Kinetics in Patients with Prostate Cancer. Journal of Nuclear Medicine, 2015, 56, 365-371.	2.8	32
68	A Clinical and Experimental Comparison of Time of Flight PET/MRI and PET/CT Systems. Molecular Imaging and Biology, 2015, 17, 714-725.	1.3	10
69	[18F]Fluoromethylcholine as a Chemotherapy Response Read-Out in Prostate Cancer Cells. Molecular Imaging and Biology, 2015, 17, 319-327.	1.3	10
70	Whole-body-MR imaging including DWIBS in the work-up of patients with head and neck squamous cell carcinoma: A feasibility study. European Journal of Radiology, 2014, 83, 1144-1151.	1.2	16
71	The use of PET-MRI in the follow-up after radiofrequency- and microwave ablation of colorectal liver metastases. BMC Medical Imaging, 2014, 14, 27.	1.4	17
72	ABCC4 Decreases docetaxel and not cabazitaxel efficacy in prostate cancer cells in vitro. Anticancer Research, 2013, 33, 387-91.	0.5	32

#	Article	IF	Citations
73	Dual-Phase PET-CT to Differentiate [18F]Fluoromethylcholine Uptake in Reactive and Malignant Lymph Nodes in Patients with Prostate Cancer. PLoS ONE, 2012, 7, e48430.	1.1	33
74	Clinical value of myocardial perfusion scintigraphy as a screening tool in liver transplant candidates. Liver Transplantation, 2011, 17, 261-269.	1.3	17